| Abbott | HGSI | Wyeth | iCo | Dyax/ImClone | Micromet | GSK | |
MedImmune's product licensees are developing several human monoclonal antibody drug candidates, which are at various stages of clinical development, as well as a few vaccine candidates.
HUMIRA® is marketed by Abbott as a treatment for rheumatoid arthritis in over 50 countries worldwide, in early rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease in several European countries and the US. It is also currently being developed for juvenile rheumatoid arthritis, chronic plaque psoriasis and ulcerative colitis.
ABT-874 is being developed for psoriasis and Crohn's disease, LymphoStat-B™ for systemic lupus erythematosus, HGS-ETR1 and HGS-ETR2 for cancer, ABthrax™ for anthrax infection and MYO-029 for muscular dystrophy. Further licensed product candidates are in pre-clinical development and in discovery.
Our patent licensees are developing a further three human monoclonal antibody drug candidates, MT201 for carcinomas and IMC-11F8 and IMC-1121B for cancer.
In 2000, MedImmune granted GlaxoSmithKline (GSK) a worldwide, exclusive license to its Streptococcus pneumoniae vaccine technology in exchange for an up-front payment and future milestones totaling more than $30 million, plus royalties on product sales. Under the terms of the agreement, GSK is responsible for all clinical development, manufacturing and sales and marketing activities for the S. pneumoniae vaccine. MedImmune completed the technology transfer to GSK by the fourth quarter of 2000. The technology licensed to GSK was originally developed in collaboration with Human Genome Sciences, Inc. and St. Jude's Childrens Research Hospital. GSK began human clinical testing in November 2003 and the program is currently in Phase 1.
